Q2 2024 revenue was $7.8 million, which represents a 10% decrease from Q2 2023 Total installed base of 363 optical genome mapping (OGM) systems as of Q2 2024, which represents a 29% increase over Q2 2023 Sold 6,165 nanochannel array flowcells in Q2 2024, which represents a 13% decrease from the number of flowcells sold in Q2 2023 The editorial panel of the American Medical Association (AMA) established a new Category I Current Procedural Terminology (CPT®) code for the use of OGM in cytogenomic genome-wide ...

Conference Call & Webcast Details CONTACTS SAN DIEGO, July 31, 2024 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (NASDAQ:BNGO) today announced that it will host a conference call and live webcast on Wednesday, August 7, 2024, at 4:30 p.m. Eastern Time to report financial results for the second quarter 2024 and to highlight recent corporate progress. Participants may access a live webcast of the call on the Investors page of the Bionano website. A replay of the conference call and webcast will be archived on B ...

Multiple myeloma is a type of blood cancer originating in the plasma cell, known as a plasma cell neoplasm (PCN), and though sensitive and accurate identification of genetic abnormalities in MM samples is critical for patient risk stratification, predication of response to therapy options, and understanding of pathogenesis, many genome analysis methodologies, including fluorescence in situ hybridization (FISH) and chromosomal microarray (CMA), are limited in their ability to detect complex gene rearrangemen ...

sees the genome through OGM solutions, diagnostic services and software. The Company offers OGM solutions for applications across basic, translational and clinical research. The Company also offers an industryleading, platform-agnostic genome analysis software solution and nucleic acid extraction and purification solutions using proprietary isotachophoresis (ITP) technology. Through its Lineagen, Inc. d/b/a Bionano Laboratories business, the Company also offers OGM-based diagnostic testing services. For mor ...

At a sponsored scientific workshop titled "Revolutionizing hematological disease: unraveling genomic mysteries with optical genome mapping," Su Yang, CG (ASCP), from The University of Texas MD Anderson Cancer Center, will present cancer research case studies that demonstrate OGM's ability to detect structural abnormalities in hematological samples at high sensitivity and resolution. | --- | --- | --- | --- | |---------------------|----------------------------------------------------------------------------- ...

As part of a sponsored session titled "High-resolution genome integrity assessment in stem cell therapy development with optical genome mapping," three experts will discuss the critical role of OGM in assessing the genome integrity and off-target events in engineered cells, specifically within the context of stem cell research. Presentations will cover OGM's utility for monitoring genomic integrity and off-target effects in cell lines and its potential to improve the quality, safety, and overall risk profil ...

The establishment of a new Category I CPT code for OGM implies that it has met the standards of acceptance by the medical community, in contrast to a Category III code, which is generally applied to emerging technologies. As part of the application review process, the panel collects input from stakeholders across the health care community to ensure CPT content reflects the coding and data-driven demands of modern health care. About Bionano Laboratories: About Bionano For more information, visit www.bionano. ...

Healthcare stocks often hold significant potential due to the constant demand for medical advancements. However, not all companies in this sector are poised for growth. Some face challenges that make them less attractive investments. Three healthcare stocks, in particular, should be approached with caution. Despite the initial appeal, these firms may not provide the best value for money in the market. Their issues range from regulatory setbacks to financial instability, making them risky choices for investo ...

SAN DIEGO, May 28, 2024 (GLOBE NEWSWIRE) -- Bionano Genomics Inc. ("Bionano" or the "Company") (NASDAQ:BNGO) today announced that it has completed a private placement of senior secured convertible debentures due May 24, 2026. The Company received gross proceeds of $18.0 million in connection with the placement, which will allow the Company to completely retire the convertible debt financing previously entered into first in October 2023, and then subsequently amended in February 2024. This new financing rein ...

SAN DIEGO, May 09, 2024 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (NASDAQ:BNGO) today announced significant upgrades to its suite of computational tools for comprehensive cancer analysis. These advancements to the company's VIA™ software solution enhance the detection and interpretation of aneusomies, and improve the analysis, visualization, interpretation, and reporting of data types including optical genome mapping (OGM), next generation sequencing, and microarray, for comprehensive assessment of hematol ...